Patents by Inventor Shizhong Liang

Shizhong Liang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF ANTI-OX40 ANTIBODY IN TREATMENT OF TUMOR OR CANCER
    Publication number: 20230416386
    Abstract: The use of an anti-OX40 antibody or an antigen-binding fragment in the treatment of a tumor or cancer, is described. Also described is a treatment method of a tumor or cancer and includes administering to a patient in need an effective amount of an anti-OX40 antibody or an antigen-binding fragment. Kits including an anti-OX40 antibody or an antigen-binding fragment are also described.
    Type: Application
    Filed: November 18, 2021
    Publication date: December 28, 2023
    Applicant: Bio-Thera Solutions, Ltd.
    Inventors: Shizhong LIANG, Binghui LIANG, Jin-Chen YU, Xiao LI, Shuqiang SONG, Shengfeng LI
  • DEVELOPMENT AND APPLICATION OF IMMUNE CELL ACTIVATOR
    Publication number: 20230139700
    Abstract: The development and use of an anti-OX40 antibody and immune cell activation is disclosed. The anti-OX40 antibody or a fragment of the anti-OX40 antibody retains strong binding to human OX40 or Rhesus Monkey OX40. The anti-OX40 antibody or a fragment of the anti-OX40 antibody more effectively activates T cells, generates stronger immune responses, and improves anti-tumor activity.
    Type: Application
    Filed: March 22, 2021
    Publication date: May 4, 2023
    Applicant: Bio-Thera Solutions, Ltd.
    Inventors: Shizhong LIANG, Dandan ZHENG, Jin-Chen YU, Shengfeng LI
  • ANTIBODY BINDING TO PD-1
    Publication number: 20220204623
    Abstract: Disclosed herein are antibodies that bind to PD-1, comprising one or more CDRs selected from the amino acid sequences of SEQ ID NOs: 13, 14, 15, 16, 17, and 18. The antibodies have high affinity and low dissociation rate for PD-1, as well as the activity for neutralizing PD-1 in vitro. The antibodies disclosed herein can be full-length antibodies or antigen-binding fragments thereof. The antibodies can be used for detecting PD-1 and the like.
    Type: Application
    Filed: April 9, 2020
    Publication date: June 30, 2022
    Inventors: Haitao Yue, Jian Lin, Shujun Pei, Shizhong Liang, Shengfeng LI